Therapy News and Research

RSS

HeartWare receives FDA approval for new left ventricular assist device

The U.S. Food and Drug Administration today approved the HeartWare Ventricular Assist System, a left ventricular assist device (LVAD), to support heart function and blood flow in patients with end-stage heart failure who are awaiting a heart transplant.

21 Nov 2012

Novel technology can lead to more efficient and cheaper therapy for Pompe disease

VIB researchers from UGent and Vrije Universiteit Brussel , together with a team of the firm Oxyrane have developed a new technology that can lead to a more efficient and possibly also cheaper therapy for diseases such as Pompe disease. Oxyrane will now start developing a clinical program for this therapy in Pompe disease.

21 Nov 2012

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

NeuroDerm, Ltd. announced today that enrollment of healthy subjects is ongoing in its Phase I clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously via a subcutaneous delivery patch device. It is designed to provide steady levodopa blood levels and enhanced bioavailability of oral levodopa for the reduction of motor complications in Parkinson's disease.

21 Nov 2012

Concord Medical third quarter 2012 total net revenues increase 65.2% to RMB206.1 million

Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China and the parent of Chang'an Hospital, today reported its unaudited consolidated financial results for the third quarter ended September 30, 2012.

21 Nov 2012

Synthetic membrane channels can be constructed through DNA nanotechnology

As reported in the journal Science, physicists at the Technische Universitaet Muenchen (TUM) and the University of Michigan have shown that synthetic membrane channels can be constructed through "DNA nanotechnology."

21 Nov 2012

Facts about Homecare

Millions of seniors and people living with disabilities will enjoy Thanksgiving and other holidays in the comfort and safety of their own homes thanks to home medical equipment and services such as oxygen therapy, hospital beds, and wheelchairs.

21 Nov 2012

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

Bristol-Myers Squibb and Pfizer announced today that the European Commission has approved ELIQUIS (apixaban) for prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors.

21 Nov 2012

FDA approves HeartWare Ventricular Assist System to treat end-stage heart failure

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has received approval from the United States Food and Drug Administration (FDA) for the HeartWare Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure.

20 Nov 2012

Nasal spray sufficient for allergic rhinitis in Japanese patients

Intranasal corticosteroid sprays can be administered as a first-line treatment for Japanese patients with seasonal allergic rhinitis, without the need to use systemic corticosteroid drugs, suggest study findings.

20 Nov 2012

A closer look into the meningitis outbreak's unwitting enablers

Randall Kinnard's legal clients had steroids injected into their backs last summer for a wide range of reasons. ... Now the 25 -- or their survivors -- have engaged Mr. Kinnaird, one of Nashville's leading lawyers, to sue the New England Compounding Center.

20 Nov 2012

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Scientists from the UK Defence Science and Technology Laboratory (Dstl) report, in a preliminary study, that they have demonstrated that a single dose of Aradigm Corporation's liposomal ciprofloxacin formulation Lipoquin administered 24 hours after exposure to a lethal dose of the bacterium Yersinia pestis provided full protection in a murine model of pneumonic plague.

20 Nov 2012

Music therapy can be beneficial to patients before and after surgical procedures

A new study review published by the University of Kentucky found that music therapy can be beneficial to patients before, during and after a surgical procedure and may reduce pain and recovery time.

20 Nov 2012

USPTO issues Notice of Allowance to Sanovas’ nested balloon catheter

Sanovas, Inc., a life science technology company focused on developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's nested balloon catheter for localized drug delivery, a component of Sanovas' Vas Zeppelin Smart Catheter technology portfolio.

20 Nov 2012

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).

20 Nov 2012

Illuminate PatientView to be introduced at Radiological Society of North America meeting

Illuminate PatientView, the newest application of Softek Illuminate's search engine and data aggregation technology, will be introduced at the Radiological Society of North America's annual meeting Nov. 25-30 at Chicago's McCormick Place and demonstrated by Softek associates in booth 9141.

20 Nov 2012

Combination of perifosine and temsirolimus shows promise against malignant glioma

Aeterna Zentaris Inc. today announced that perifosine, its oral AKT inhibitor, combined with temsirolimus ("TEM"), was well tolerated in an investigator driven Phase 1 clinical trial in recurrent or progressive malignant glioma ("MG").

20 Nov 2012

Ventus Medical introduces Provent Sleep Apnea Therapy in Canada

Ventus Medical is pleased to announce the introduction of its proprietary Provent Sleep Apnea Therapy into Canada. Provent Therapy is an innovative, non-invasive treatment for obstructive sleep apnea (OSA).

20 Nov 2012

Boston and Cincinnati Children's Hospital to learn more about how autism develops

A network of five leading medical centers, led by Cincinnati Children's Hospital Medical Center and Boston Children's Hospital, has received a five-year, $12.5 million National Institutes of Health (NIH) grant to learn more about how autism develops.

20 Nov 2012

Diffusion Pharmaceuticals completes trans sodium crocetinate Phase I trial on glioblastoma

Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments, today announced that it has successfully completed a Phase I clinical trial of its lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary brain cancer (glioblastoma or GBM).

19 Nov 2012

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

19 Nov 2012

Therapy News and Research

HeartWare receives FDA approval for new left ventricular assist device

Novel technology can lead to more efficient and cheaper therapy for Pompe disease

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

Concord Medical third quarter 2012 total net revenues increase 65.2% to RMB206.1 million

Synthetic membrane channels can be constructed through DNA nanotechnology

Facts about Homecare

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

FDA approves HeartWare Ventricular Assist System to treat end-stage heart failure

Nasal spray sufficient for allergic rhinitis in Japanese patients

A closer look into the meningitis outbreak's unwitting enablers

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Music therapy can be beneficial to patients before and after surgical procedures

USPTO issues Notice of Allowance to Sanovas’ nested balloon catheter

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Illuminate PatientView to be introduced at Radiological Society of North America meeting

Combination of perifosine and temsirolimus shows promise against malignant glioma

Ventus Medical introduces Provent Sleep Apnea Therapy in Canada

Boston and Cincinnati Children's Hospital to learn more about how autism develops

Diffusion Pharmaceuticals completes trans sodium crocetinate Phase I trial on glioblastoma

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News